Esperion Therapeutics (acquired) Overview

  • Founded
  • 1998
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 21
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $5M
Latest Deal Amount

Esperion Therapeutics (acquired) General Information

Description

Developer of pharmaceutical products for the treatment of cardiovascular and metabolic diseases. The company engages in research, development, and commercialization of oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 46701 Commerce Center Drive
  • Suite B
  • Plymouth, MI 48170
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Esperion Therapeutics (acquired) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 28-Apr-2008 $5M 000 Completed Clinical Trials - Phase 2
5. Merger/Acquisition 01-Jan-2004 00.00 000.00 00.00 Completed Clinical Trials - Phase 2
4. IPO 09-Aug-2000 000.00 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 13-Jan-2000 0000 000.00 Completed Startup
2. Early Stage VC $6.2M Completed Startup
1. Debt - General 08-Nov-1999 $6.2M $6.2M Completed Startup
To view Esperion Therapeutics (acquired)’s complete valuation and funding history, request access »

Esperion Therapeutics (acquired) Executive Team (1)

Name Title Board Seat Contact Info
Roger Newton Ph.D Co-Founder, Executive Chairman, Board Member & Chief Scientific Officer
To view Esperion Therapeutics (acquired)’s complete executive team members history, request access »

Esperion Therapeutics (acquired) Board Members (2)

Name Representing Role Since
Roger Newton Ph.D Self Co-Founder, Executive Chairman, Board Member & Chief Scientific Officer 000 0000
To view Esperion Therapeutics (acquired)’s complete board members history, request access »

Esperion Therapeutics (acquired) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Esperion Therapeutics (acquired) Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Canaan Partners Venture Capital Minority 000 0000 000000 0
HealthCap Venture Capital Minority 000 0000 000000 0
Oak Investment Partners Venture Capital Minority 000 0000 000000 0
Pfizer Corporation Minority 000 0000 000000 0
Scheer & Company Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »